Navigation Links
Novo Nordisk Inc. Appoints Eddie Li as Vice President, Regulatory Affairs
Date:9/7/2011

PRINCETON, N.J., Sept. 7, 2011 /PRNewswire/ -- Novo Nordisk Inc. announced today that Dr. Eddie Li, has been appointed to join the diabetes leader as Vice President, Regulatory Affairs starting September 12.

Reporting to Anne Philips, M.D., Corporate Vice President, Clinical Development, Medical and Regulatory Affairs for North America, Dr. Li brings over 20 years of industry, public sector, and academic experience in the field of regulatory affairs and safety.  He'll be leading Novo Nordisk's U.S. regulatory team, and maintain relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the U.S. Food and Drug Administration's (FDA) review and approval process.

"Eddie has worked within the FDA and other pharmaceutical peers so he brings a wealth of experience to Novo Nordisk.  He comes to us at a critical time in our company as our portfolio continues to grow," said Anne Phillips, M.D., corporate vice president, Clinical, Medical and Regulatory Affairs.  "The regulatory environment is becoming increasingly complex, and Eddie's background suits our needs to have a senior leader as our main point of contact with the FDA."

Originally trained in medicine and toxicology, Dr. Li has an extensive background in the pharmaceutical industry, joining Novo Nordisk from Sanofi, where he most recently was global head of regulatory affairs for one of its largest therapy areas.  He has also worked at Johnson & Johnson and AstraZeneca.  He also served as a staff reviewer at the FDA.

Eddie studied in the Shanghai First Medical College.  He subsequently completed his Ph.D. in Toxicology at the University of Arkansas for Medical Sciences, and also studied in an M.B.A. program at the University of Delaware.

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care.  The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy.  For more information, visit www.novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs
2. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters
3. Novo Nordisk A/S: PharmaVitae Profile
4. Video from Novo Nordisk A/S available on thenewsmarket.com: Novo Nordisk Receives Approval for Victoza in China
5. Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval
6. Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders
7. Novo Nordisk Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case
8. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
9. Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
10. Novo Nordisk and Chip Ganassi Racing Team Up for 2011 IZOD IndyCar Series
11. Novo Nordisk and Entertainment Industries Council Work Together to Improve Public Education and Awareness about Diabetes Epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
(Date:10/12/2017)... ... October 12, 2017 , ... In ... taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, ... overseas retirement havens have extremely low property-tax rates, which contributes to the relatively ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... at the University of California Berkeley, and other leading institutions in announcing the ... power of institutions to change the way animals are raised for food. , ...
(Date:10/12/2017)... Antonio, Texas (PRWEB) , ... October 12, 2017 ... ... device and biologics manufacturer, has expanded its executive staff with the addition of ... , In this role, Slott will develop the national distribution and sales network, ...
Breaking Medicine News(10 mins):